Market Research Reports, Inc. has announced the addition of “PharmaPoint: Parkinson’s Disease - Global Drug Forecast and Market Analysis to 2022” research report to their website http://www.marketresearchreports.com
Lewes, DE -- (SBWIRE) -- 06/13/2014 -- Global Parkinson’s Disease Therapeutics Market Value to Reach $5.3 Billion by 2022, as Current Pipeline Addresses Advanced Patients’ Needs, says Publisher
As the prevalence of Parkinson’s Disease (PD) continues to grow thanks to an ageing population, its treatment market value is expected to increase from $3.6 billion in 2012 to $5.3 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 4%, says research and consulting firm by Publisher.
According to the company’s latest report*, the US will have the largest PD therapeutics market share of 44% by 2022, expanding from 32% in 2012. This will be followed by Japan, Brazil and Germany, with respective shares of 13%, 11% and 10%.
According to Senior Analyst, says: “PD therapy is currently limited to symptomatic treatment, but since this is a chronic and progressive disorder, patients and physicians are waiting anxiously for a treatment that slows or stops this progression.
“Several strategies are already under investigation, including compounds or biological agents that administer growth factors, prevent neuroinflammation and target ?-synuclein.”
While Publisher does not expect a disease-modifying treatment to be introduced during the forecast period, several pipeline programs are underway to reach this goal.
According to Analyst, says: “Most of the late-stage pipeline agents are set to meet the needs of advanced patients, with five therapies expected to launch by 2022. These include Rytary, Civitas’ CVT-301, opicapone, safinamide, and tozadenant. Of these, CVT-301, opicapone, and tozadenant will be used almost exclusively in advanced patients.”
Current unmet needs in the PD treatment market, such as complications in advanced-stage patients known as wearing-off and dyskinesia, will also be addressed during the forecast period, according to Publisher.
“During the coming decade, wearing-off will most likely be addressed by CVT-301 directly. Other pipeline therapies, including Rytary and opicapone, may also prevent the emergence of wearing-off symptoms,” Leach concludes.
PharmaPoint: Parkinson’s Disease - Global Drug Forecast and Market Analysis to 2022 report provides annualized Parkinson’s Disease (PD) market revenue, annual cost of therapy and treatment usage pattern data from 2012 to 2022. Key topics include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PD treatment market in the seven major countries - the US, France, Italy, Germany, Spain, the UK and Brazil.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by Publisher’s team of industry experts.
For more information see - http://mrr.cm/ZQd
Find all Healthcare Reports at: http://www.marketresearchreports.com/healthcare
About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.
Follow us on Vimeo : http://vimeo.com/marketresearchreports